These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21697728)

  • 1. Cost-effectiveness of levosimendan in patients with acute heart failure.
    Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
    J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
    de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
    J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy.
    Lucioni C; D'Ambrosi A; Mazzi S; Pollesello P; Apajasalo M; Fedele F
    Adv Ther; 2012 Dec; 29(12):1037-50. PubMed ID: 23233357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study.
    de Lissovoy G; Fraeman K; Teerlink JR; Mullahy J; Salon J; Sterz R; Durtschi A; Padley RJ
    Eur J Health Econ; 2010 Apr; 11(2):185-93. PubMed ID: 19582491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan: a retrospective single-center case series.
    Berry WT; Hewson RW; Langrish CJ; McKenzie CA; Barrett NA
    J Crit Care; 2013 Dec; 28(6):1075-8. PubMed ID: 23998721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case.
    Mardiguian S; Kivikko M; Heringlake M; Smare C; Bertranou E; Apajasalo M; Pollesello P
    J Med Econ; 2016; 19(5):506-14. PubMed ID: 26707159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of levosimendan in cardiac surgery patients with poor left ventricular function.
    De Hert SG; Lorsomradee S; Cromheecke S; Van der Linden PJ
    Anesth Analg; 2007 Apr; 104(4):766-73. PubMed ID: 17377079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
    Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
    Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
    J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine].
    Oliveira MT; Follador W; Martins ML; Canaviera R; Tsuji RL; Scipioni A; Barretto AC
    Arq Bras Cardiol; 2005 Jul; 85(1):9-14. PubMed ID: 16041448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone.
    Nanas JN; Papazoglou P; Tsagalou EP; Ntalianis A; Tsolakis E; Terrovitis JV; Kanakakis J; Nanas SN; Alexopoulos GP; Anastasiou-Nana MI
    Am J Cardiol; 2005 Mar; 95(6):768-71. PubMed ID: 15757608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan for primary graft failure after heart transplantation: a 3-year follow-up.
    Beiras-Fernandez A; Kur F; Kaczmarek I; Frisch P; Weis M; Reichart B; Weis F
    Transplant Proc; 2011; 43(6):2260-2. PubMed ID: 21839251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.